Market revenue in 2023 | USD 320.7 million |
Market revenue in 2030 | USD 510.4 million |
Growth rate | 6.9% (CAGR from 2023 to 2030) |
Largest segment | Phase iii |
Fastest growing segment | Phase I |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Phase I, Phase II, Phase III, Phase IV |
Key market players worldwide | Thermo Fisher Scientific Inc, Icon PLC, Charles River Laboratories International Inc, IQVIA Holdings Inc, Syneos Health, SGS AG, PAREXEL, Wuxi AppTec Co Ltd, Labcorp Holdings Inc, Eli Lilly and Co, Novo Nordisk A/S ADR, Pfizer Inc, Caidya |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to clinical trials market will help companies and investors design strategic landscapes.
Phase iii was the largest segment with a revenue share of 53.2% in 2023. Horizon Databook has segmented the Mexico clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
Mexico is an attractive destination for outsourcing clinical trials as cost plays a major factor. Moreover, the proximity to the U.S. and the availability of investigators in urban areas also help in cost-cutting. As the population here cannot afford treatment of chronic diseases, they usually prefer participating in such trials.
Hence, availability of a diverse patient pool is one of the key regional market drivers. Favorable policies by the Federal Commission for the Protection against Sanitary Risk (COFEPRIS), including shortening setup time for clinical trials to 2 months, have attracted many clients. In addition, there have been major investments in infrastructure development to provide better healthcare and clinical facilities.
The increasing number of trials outsourced to this country has brought about many regulatory changes favoring growth. The Mexican government has established the Federal Commission for Protection against Sanitary Risks, which has improved the regulatory environment. The average time to set up a clinical trial process is 3 to 4 months.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into Mexico clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account